REGENXBIO (NASDAQ:RGNX) Rating Increased to Hold at StockNews.com

REGENXBIO (NASDAQ:RGNX) was upgraded by investment analysts at StockNews.com from a “sell” rating to a “hold” rating in a report issued on Friday.

A number of other equities research analysts have also recently commented on RGNX. Morgan Stanley reiterated an “overweight” rating and set a $22.00 target price on shares of REGENXBIO in a report on Friday, November 15th. Royal Bank of Canada reiterated an “outperform” rating and set a $30.00 target price on shares of REGENXBIO in a report on Tuesday, January 21st. Raymond James began coverage on REGENXBIO in a report on Friday. They set an “outperform” rating and a $27.00 target price on the stock. Chardan Capital reiterated a “buy” rating and set a $52.00 target price on shares of REGENXBIO in a report on Wednesday, November 20th. Finally, HC Wainwright reiterated a “buy” rating and set a $36.00 target price on shares of REGENXBIO in a report on Wednesday, January 15th. Two research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to data from MarketBeat, REGENXBIO currently has an average rating of “Moderate Buy” and a consensus target price of $35.64.

REGENXBIO Stock Down 2.6 %

Shares of RGNX traded down $0.22 on Friday, reaching $8.21. The stock had a trading volume of 539,571 shares, compared to its average volume of 1,054,836. The firm has a market capitalization of $406.72 million, a PE ratio of -1.63 and a beta of 1.29. The firm has a 50-day moving average of $8.11 and a 200 day moving average of $10.10. REGENXBIO has a twelve month low of $6.56 and a twelve month high of $28.80.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Redmile Group LLC raised its position in shares of REGENXBIO by 7.1% in the 3rd quarter. Redmile Group LLC now owns 4,892,902 shares of the biotechnology company’s stock worth $51,327,000 after buying an additional 323,100 shares during the period. Geode Capital Management LLC raised its position in shares of REGENXBIO by 4.2% in the 3rd quarter. Geode Capital Management LLC now owns 1,088,651 shares of the biotechnology company’s stock worth $11,422,000 after buying an additional 44,037 shares during the period. Assenagon Asset Management S.A. raised its position in shares of REGENXBIO by 53.0% in the 4th quarter. Assenagon Asset Management S.A. now owns 856,572 shares of the biotechnology company’s stock worth $6,621,000 after buying an additional 296,700 shares during the period. Charles Schwab Investment Management Inc. raised its position in shares of REGENXBIO by 9.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 417,739 shares of the biotechnology company’s stock worth $4,382,000 after buying an additional 37,055 shares during the period. Finally, Millennium Management LLC raised its position in shares of REGENXBIO by 84.8% in the 2nd quarter. Millennium Management LLC now owns 306,487 shares of the biotechnology company’s stock worth $3,586,000 after buying an additional 140,666 shares during the period. Hedge funds and other institutional investors own 88.08% of the company’s stock.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.